國立高雄大學圖資館 |

Language: English

Back

Next generation antibody drug conjug...

Barth, Stefan.

Next generation antibody drug conjugates (ADCs) and immunotoxins

Record Type:	Electronic resources : Monograph/item
Title/Author:	Next generation antibody drug conjugates (ADCs) and immunotoxinsedited by Ulf Grawunder, Stefan Barth.
other author:	Grawunder, Ulf.
Published:	Cham :Springer International Publishing :2017.
Description:	xi, 181 p. :ill., digital ;24 cm.
Contained By:	Springer eBooks
Subject:	Antibody-toxin conjugates.
Online resource:	http://dx.doi.org/10.1007/978-3-319-46877-8
ISBN:	9783319468778$q(electronic bk.)

Next generation antibody drug conjugates (ADCs) and immunotoxins
Next generation antibody drug conjugates (ADCs) and immunotoxins[electronic resource] /edited by Ulf Grawunder, Stefan Barth. - Cham :Springer International Publishing :2017. - xi, 181 p. :ill., digital ;24 cm. - Milestones in drug therapy,2296-6056. - Milestones in drug therapy..

Chemical Assembly of Antibody-Drug Conjugates -- Pre-clinical evaluation of ADCs delivering highly potent pyrrolobenzodiazepine (PBD) dimers -- Stable and homogeneous drug conjugation by sequential bis-alkylation at disulfide bonds using bis-sulfone reagents -- Calicheamicin antibody-drug conjugates for liquid- and solid tumor indications -- Enzyme-based strategies to generate site-specifically conjugated Antibody Drug Conjugates -- Substance P - Saporin for the Treatment of Intractable Pain -- Recombinant immunotoxins for Chronic Inflammatory Disease -- BL22: A milestone in targeting CD22.

This book describes the newest developments in antibody drug conjugates and immunotoxins, paving their way to clinical application. Lessons learned from the current state of the art are used to further improve our understanding of their mechanisms of action and off target activities. The book introduces scientists to all of the prerequisites that must be properly addressed, including identification of the right target, specific traits of target binding antibodies, proper selection of the toxic payload, internalization induced by binding, and next generation conjugation and linker technologies. These knowledge-based, revolutionary new drug principles will form the cornerstone of the future standard of care and will lead to major advances in application, as well as improved quality of life and patient survival rates. This book will be of interest to biotech companies and researchers working in the fields of immunology, pharmacology, and oncology.

ISBN: 9783319468778$q(electronic bk.)

Standard No.: 10.1007/978-3-319-46877-8doiSubjects--Topical Terms:

197357
Antibody-toxin conjugates.

LC Class. No.: RS431.A64

Dewey Class. No.: 615.798

Next generation antibody drug conjugates (ADCs) and immunotoxins
LDR:02580nmm a2200325 a 4500 001 511781
003 DE-He213
005 20170407150027.0
006 m d
007 cr nn 008maaau
008 171226s2017 gw s 0 eng d
020 $a 9783319468778$q(electronic bk.)
020 $a 9783319468754$q(paper)
024 7 $a 10.1007/978-3-319-46877-8 $2 doi
035 $a 978-3-319-46877-8
040 $a GP $c GP
041 0 $a eng
050 4 $a RS431.A64
072 7 $a MMG $2 bicssc
072 7 $a MED071000 $2 bisacsh
082 0 4 $a 615.798 $2 23
090 $a RS431.A64 $b N567 2017
245 0 0 $a Next generation antibody drug conjugates (ADCs) and immunotoxins $h [electronic resource] / $c edited by Ulf Grawunder, Stefan Barth.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2017.
300 $a xi, 181 p. : $b ill., digital ; $c 24 cm.
490 1 $a Milestones in drug therapy, $x 2296-6056
505 0 $a Chemical Assembly of Antibody-Drug Conjugates -- Pre-clinical evaluation of ADCs delivering highly potent pyrrolobenzodiazepine (PBD) dimers -- Stable and homogeneous drug conjugation by sequential bis-alkylation at disulfide bonds using bis-sulfone reagents -- Calicheamicin antibody-drug conjugates for liquid- and solid tumor indications -- Enzyme-based strategies to generate site-specifically conjugated Antibody Drug Conjugates -- Substance P - Saporin for the Treatment of Intractable Pain -- Recombinant immunotoxins for Chronic Inflammatory Disease -- BL22: A milestone in targeting CD22.
520 $a This book describes the newest developments in antibody drug conjugates and immunotoxins, paving their way to clinical application. Lessons learned from the current state of the art are used to further improve our understanding of their mechanisms of action and off target activities. The book introduces scientists to all of the prerequisites that must be properly addressed, including identification of the right target, specific traits of target binding antibodies, proper selection of the toxic payload, internalization induced by binding, and next generation conjugation and linker technologies. These knowledge-based, revolutionary new drug principles will form the cornerstone of the future standard of care and will lead to major advances in application, as well as improved quality of life and patient survival rates. This book will be of interest to biotech companies and researchers working in the fields of immunology, pharmacology, and oncology.
650 0 $a Antibody-toxin conjugates. $3 197357
650 1 4 $a Biomedicine. $3 273648
650 2 4 $a Pharmacology/Toxicology. $3 273652
650 2 4 $a Antibodies. $3 456407
650 2 4 $a Pharmacotherapy. $3 615025
650 2 4 $a Cancer Research. $3 273660
650 2 4 $a Oncology. $3 195181
700 1 $a Grawunder, Ulf. $3 779249
700 1 $a Barth, Stefan. $3 779250
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer eBooks
830 0 $a Milestones in drug therapy. $3 557479
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-46877-8
950 $a Biomedical and Life Sciences (Springer-11642)